Department of Cardiology, Faculty of Medicine, University of Tsukuba, Tsukuba 305-8575, Japan.
Department of Cardiology, Ibaraki Prefectural Central Hospital, Kasama 309-1793, Japan.
Int J Mol Sci. 2019 Jun 10;20(11):2824. doi: 10.3390/ijms20112824.
Natriuretic peptides (NPs) have become important diagnostic and prognostic biomarkers in cardiovascular diseases, particularly in heart failure (HF). Diagnosis and management of coronary artery disease and atrial fibrillation (AF) can also be guided by NP levels. When interpreting NP levels, however, the caveat is that age, sex, body mass index, renal dysfunction, and race affect the clearance of NPs, resulting in different cut-off values in clinical practice. In AF, NP levels have been associated with incident AF in the general population, recurrences after catheter ablation, prediction of clinical prognosis, and the risk of stroke. In this article, we first review and summarize the current evidence and the roles of B-type NP and atrial NP in HF and coronary artery disease and then focus on the increasing utility of NPs in the diagnosis and management of and the research into AF.
利钠肽(NPs)已成为心血管疾病,特别是心力衰竭(HF)的重要诊断和预后生物标志物。NP 水平也可用于指导冠状动脉疾病和心房颤动(AF)的诊断和管理。然而,在解释 NP 水平时,需要注意的是,年龄、性别、体重指数、肾功能和种族会影响 NPs 的清除率,导致临床实践中的不同截断值。在 AF 中,NP 水平与一般人群中 AF 的发生、导管消融后的复发、临床预后的预测以及中风的风险有关。在本文中,我们首先回顾和总结了 B 型 NP 和心房 NP 在 HF 和冠状动脉疾病中的现有证据和作用,然后重点介绍了 NPs 在 AF 的诊断、管理和研究中的应用不断增加。